Researchers from the Gene Therapy Program (GTP) at the Perelman School of Medicine at the University of Pennsylvania presented ten research abstracts, two invited talks, and a workshop presentation highlighting translational science and discovery research on gene therapy, gene editing, and adeno-associated virus (AAV) vector technology.
View Full PostiECURE, a gene editing company started by University of Pennsylvania scientist Dr. Jim Wilson, has received FDA approval to test a form of gene editing in infants for the first time in the United States.
View Full PostGene therapy adeno-associated viruses (AAVs) - viruses that can be engineered to deliver DNA to target cells - are unlikely to cause cancer-triggering insertions in humans or monkeys and may contribute to long-term efficacy, according to new research from the University of Pennsylvania’s Gene Therapy Program (GTP).
View Full PostThe Foundation for Angelman Syndrome Therapeutics (FAST), a non-profit organization, has entered into an exclusive global collaborative research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome.
View Full PostNine researchers from the University of Pennsylvania’s Gene Therapy Program (GTP) presented abstracts highlighting their translational science and discovery research on gene therapy, gene editing, and adeno-associated virus (AAV) vector technology at the American Society of Cell and Gene Therapy (ASGCT)’s 26th Annual Meeting.
View Full Post